Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
IPO Year: 2012
Exchange: NYSE
Website: globusmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | Buy → Neutral | BTIG Research | |
| 1/10/2025 | $97.00 | Underperform → Neutral | BofA Securities |
| 12/2/2024 | $83.00 → $100.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/7/2024 | $60.00 → $78.00 | Equal Weight → Overweight | Wells Fargo |
| 5/20/2024 | $60.00 → $80.00 | Neutral → Overweight | Piper Sandler |
| 3/18/2024 | $60.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 9/19/2023 | $61.00 | Hold → Buy | Stifel |
| 3/30/2023 | $67.00 | Hold → Buy | Canaccord Genuity |
| 2/13/2023 | $83.00 → $63.00 | Buy → Underperform | BofA Securities |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
SD - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
DEFA14A - GLOBUS MEDICAL INC (0001237831) (Filer)
DEF 14A - GLOBUS MEDICAL INC (0001237831) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BTIG Research downgraded Globus Medical from Buy to Neutral
BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00
Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously
Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously
Piper Sandler upgraded Globus Medical from Neutral to Overweight and set a new price target of $80.00 from $60.00 previously
BTIG Research upgraded Globus Medical from Neutral to Buy and set a new price target of $60.00
ROTH MKM initiated coverage of Globus Medical with a rating of Buy and set a new price target of $75.00
Stifel upgraded Globus Medical from Hold to Buy and set a new price target of $61.00
Canaccord Genuity upgraded Globus Medical from Hold to Buy and set a new price target of $67.00
BofA Securities downgraded Globus Medical from Buy to Underperform and set a new price target of $63.00 from $83.00 previously
Fastest customizable press release news feed in the world
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basisGAAP net income for the quarter was $202.8 millionGAAP diluted earnings per share ("EPS") was $1.49 and non-GAAP diluted EPS was $0.86 "Q2 results were led by our US Spine business, growing 5.7%, as reported and 7.4% on a day-adjusted basis. US Spine had sustained momentum during the quarter, posting its highest sequential revenue growth since the second quarter of 2022,"
CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025. Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer. "We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings
AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webca
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. "Our goal is to revolutionize the $550 million high-speed drill market with the introduction of innovative, next generation oscillation," said David Hole, president of spine at Globus Medical. "The DuraPro™ oscillating system coupled with navigation enhances the procedural solutions we offer to surgeons to help advance pati
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. "We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation," said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. "Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforc
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain," said Dan Scavilla, president and CEO of Globus Medical. The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, andModulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system. The COHERE ™ ALIF Spacer is the latest addition to Globus Medical's Advanced Materials Science™ (AMS) implant portfolio, featuring proprietary porous surface technology designed for bone in-growth while maintaining the imaging and mechanical properties favored in a solid PEEK interbody spacer.1,2 "Porous
Live Leadership Updates
CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab
This live feed shows all institutional transactions in real time.
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
Live finance-specific insights
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basisGAAP net income for the quarter was $202.8 millionGAAP diluted earnings per share ("EPS") was $1.49 and non-GAAP diluted EPS was $0.86 "Q2 results were led by our US Spine business, growing 5.7%, as reported and 7.4% on a day-adjusted basis. US Spine had sustained momentum during the quarter, posting its highest sequential revenue growth since the second quarter of 2022,"
CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025. Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two
AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webca
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share ("EPS") was $0.19 and non-GAAP diluted EPS was $0.84Non-GAAP adjusted EBITDA was $196.9 million, or 30.0% of net sales Full Year 2024: Worldwide net sales were $2,519.4 million, an increase of 60.6% on an as-reported basis a
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news
AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering